These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 33241519)
1. Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Aizer AA; Rahman R; Guenette JP; Huang RY Eur Radiol; 2021 Jun; 31(6):4114-4129. PubMed ID: 33241519 [TBL] [Abstract][Full Text] [Related]
2. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071 [TBL] [Abstract][Full Text] [Related]
3. The Safety and Efficacy of Concurrent Immune Checkpoint Blockade and Stereotactic Radiosurgery Therapy with Practitioner and Researcher Recommendations. Mehkri Y; Windermere SA; Still MEH; Yan SC; Goutnik M; Melnick K; Doonan B; Ghiaseddin AP; Rahman M World Neurosurg; 2024 Jan; 181():e133-e153. PubMed ID: 37739175 [TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibition and single fraction stereotactic radiosurgery in brain metastases from non-small cell lung cancer: an international multicenter study of 395 patients. Lehrer EJ; Khosla AA; Ozair A; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Mathieu D; Trudel C; Deibert CP; Malouff TD; Ruiz-Garcia H; Peterson JL; Patel S; Bonney P; Hwang L; Yu C; Zada G; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Fakhoury KR; Rusthoven CG; Dickstein DR; Sheehan JP; Trifiletti DM; Ahluwalia MS J Neurooncol; 2023 Oct; 165(1):63-77. PubMed ID: 37889444 [TBL] [Abstract][Full Text] [Related]
5. Local and distant brain control in melanoma and NSCLC brain metastases with concurrent radiosurgery and immune checkpoint inhibition. Le A; Mohammadi H; Mohammed T; Burney H; Zang Y; Frye D; Shiue K; Lautenschlaeger T; Miller J J Neurooncol; 2022 Jul; 158(3):481-488. PubMed ID: 35641840 [TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with lung cancer and brain metastases: a propensity score-matched analysis. Yomo S; Oda K; Oguchi K J Neurosurg; 2023 Dec; 139(6):1628-1637. PubMed ID: 37243558 [TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review. Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050 [No Abstract] [Full Text] [Related]
9. Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy. Weingarten N; Kruser TJ; Bloch O Clin Neurol Neurosurg; 2019 Apr; 179():14-18. PubMed ID: 30784894 [TBL] [Abstract][Full Text] [Related]
10. Concurrent Administration of Immune Checkpoint Inhibitors and Single Fraction Stereotactic Radiosurgery in Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Brain Metastases. Lehrer EJ; Kowalchuk RO; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Fakhoury KR; Rusthoven CG; Mathieu D; Trudel C; Malouff TD; Ruiz-Garcia H; Bonney P; Hwang L; Yu C; Zada G; Patel S; Deibert CP; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Harmsen WS; Jones BM; Sharma S; Ahluwalia MS; Sheehan JP; Trifiletti DM Int J Radiat Oncol Biol Phys; 2023 Jul; 116(4):858-868. PubMed ID: 36690161 [TBL] [Abstract][Full Text] [Related]
11. Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study. Badrigilan S; Meola A; Chang SD; Rezaeian S; Nemati H; Almasi T; Rostampour N Br J Neurosurg; 2023 Dec; 37(6):1533-1543. PubMed ID: 34979828 [TBL] [Abstract][Full Text] [Related]
12. Long-Term Intracranial Outcomes With Combination Dual Immune-Checkpoint Blockade and Stereotactic Radiosurgery in Patients With Melanoma and Non-Small Cell Lung Cancer Brain Metastases. Vaios EJ; Shenker RF; Hendrickson PG; Wan Z; Niedzwiecki D; Winter SF; Shih HA; Dietrich J; Wang C; Salama AKS; Clarke JM; Allen K; Sperduto P; Mullikin T; Kirkpatrick JP; Floyd SR; Reitman ZJ Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1507-1518. PubMed ID: 38097090 [TBL] [Abstract][Full Text] [Related]
13. Predictors of Adverse Radiation Effect in Brain Metastasis Patients Treated With Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy. Helis CA; Hughes RT; Glenn CW; Lanier CM; Masters AH; Dohm A; Ahmed T; Ruiz J; Triozzi P; Gondal H; Cramer CK; Tatter SB; Laxton AW; Xing F; Lo HW; Su J; Watabe K; Wang G; Whitlow CT; Chan MD Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):295-303. PubMed ID: 32615262 [TBL] [Abstract][Full Text] [Related]
14. Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. Sha CM; Lehrer EJ; Hwang C; Trifiletti DM; Mackley HB; Drabick JJ; Zaorsky NG Radiother Oncol; 2020 Oct; 151():141-148. PubMed ID: 32717359 [TBL] [Abstract][Full Text] [Related]
15. Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases. Koenig JL; Shi S; Sborov K; Gensheimer MF; Li G; Nagpal S; Chang SD; Gibbs IC; Soltys SG; Pollom EL World Neurosurg; 2019 Jun; 126():e1399-e1411. PubMed ID: 30902777 [TBL] [Abstract][Full Text] [Related]
16. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. Sneed PK; Mendez J; Vemer-van den Hoek JG; Seymour ZA; Ma L; Molinaro AM; Fogh SE; Nakamura JL; McDermott MW J Neurosurg; 2015 Aug; 123(2):373-86. PubMed ID: 25978710 [TBL] [Abstract][Full Text] [Related]
17. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases. Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062 [TBL] [Abstract][Full Text] [Related]
18. Timing of stereotactic radiosurgery within the first-line systemic treatment in non-small cell lung cancer brain metastases: a retrospective single-center cohort study. Bodensohn R; Kolorz A; Reis J; Werner S; Forbrig R; Garny S; Taugner J; de Colle C; Belka C; Manapov F; von Baumgarten L; Niyazi M Transl Lung Cancer Res; 2024 Jul; 13(7):1635-1648. PubMed ID: 39118877 [TBL] [Abstract][Full Text] [Related]
19. The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Kotecha R; Kim JM; Miller JA; Juloori A; Chao ST; Murphy ES; Peereboom DM; Mohammadi AM; Barnett GH; Vogelbaum MA; Angelov L; Suh JH; Ahluwalia MS Neuro Oncol; 2019 Aug; 21(8):1060-1068. PubMed ID: 30796838 [TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Kim PH; Suh CH; Kim HS; Kim KW; Kim DY; Lee EQ; Aizer AA; Guenette JP; Huang RY Korean J Radiol; 2021 Apr; 22(4):584-595. PubMed ID: 33289357 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]